Table 1

Patient demographics and covariates in the clinical study of amodiaquine and desethylamodiaquine in pregnant and postpartum women

ParameterPregnant womenPostpartum women
Total no. of patients2719
No. of patients with P. vivax277
Total dose of amodiaquine (mg/kg) [median (range)]9.89 (9.32–10.7)10.0 (9.32–10.7)
Continuous covariates [median (range)]
    Age (yr)23 (16–39)23 (18–35)
    Body wt (kg)49 (37–68)44 (38–57)
    Height (cm)152 (137–164)150 (137–164)
    BMI (kg/m2)21.6 (17.3–25.2)19.6 (16.8–22.6)
    Pulse (min−1)84 (62–120)80 (68–92)
    Temperature (°C)36.5 (35.8–40.2)36.8 (36.0–37.6)
    Estimated gestational age (wk)27.6 (13.0–37.4)NAa
    Parasitemia (no. of parasite/μl)624 (96.0–50,400)200 (0–7,810)
    Hematocrit (%)33.2 (22.8–39.8)35.9 (22.3–42.1)
    Bilirubin (mg/dl)0.450 (0.150–1.46)0.330 (0.190–0.330)
    Platelet (103/μl)172 (84.0–322)262 (90.0–334)
Categorical covariates
    Smokers (%)8 (29.6)6 (31.5)
Outcome [no. (%)]
Patients lost during follow-up3 (11.1)1 (5.26)
Patients with no recurrent malaria infection10 (37.0)18 (94.7)
Patients with recurrent P. vivax infection10 (37.0)0 (0)
Patients with novel P. falciparum infection4 (14.8)0 (0)
  • a NA, not applicable.